A Phase 3 interventional study of Nivolumab and Cetuximab in Squamous Cell Carcinoma of the Head and Neck, sponsored by Bristol-Myers Squibb. Completed at 55 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-08-09.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies testing nivolumab in Squamous Cell Carcinoma of Head and Neck — 11 open to participants now, 15 under way, 2 of them phase 3. Nivolumab · Squamous Cell Carcinoma of Head and Neck.
Among the 46 studies testing nivolumab in Squamous Cell Carcinoma of Head and Neck, this one is the 13th largest by enrollment, is one of 8 that started in 2017, is one of 6 in phase 3, and was the 9th registered.
2,019 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.
Browse Squamous Cell Carcinoma of Head and Neck studies →11 of the 46 studies testing nivolumab in Squamous Cell Carcinoma of Head and Neck are open now, in 7 countries. Recruiting first, the newest first:
Vanderbilt-Ingram Cancer Center · Sites in United States
Ages 18+
The Netherlands Cancer Institute · Sites in Netherlands
Ages 18+
National University Hospital, Singapore · Sites in Singapore
Ages 21–99
Mayo Clinic · Sites in United States
Ages 18+
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18–70
By country, each count listing its studies:
Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 435 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 311 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, nivolumab is the treatment under test here. Read study by study →
46 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 32 · Phase 3 7
First in 2014; this study’s year is marked. 8 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 74 is above the median of 48 across 1,653 interventional studies indexed under Squamous Cell Carcinoma of Head and Neck.
Median enrollment 44 across the 46 interventional studies. Of the 27 that completed or were terminated, 18 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 46 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
12 studies in Squamous Cell Carcinoma of Head and Neck by Bristol-Myers Squibb: 1 open now, 2 under way, none of them phase 3. Of 10 finished, 3 (30%) have results posted.
Among the 12 studies in Squamous Cell Carcinoma of Head and Neck by Bristol-Myers Squibb, this one is the only one that started in 2017, is one of 2 in phase 3, and was the 6th registered.
Bristol-Myers Squibb’s Squamous Cell Carcinoma of Head and Neck studies by the year they started, since 2008.
5 of the studies testing nivolumab in Squamous Cell Carcinoma of Head and Neck that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03576417Phase 3Groupe Oncologie Radiotherapie Tete et CouA Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck | 2027-08 |
| NCT05136196National Cancer Institute (NCI)BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study | 2027-01-01 |
| NCT06265285Mayo ClinicComparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program | 2027-05-01 |
| NCT04831320Washington University School of MedicineNab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor | 2027-06-30 |
| NCT03406247Gustave Roussy, Cancer Campus, Grand ParisAdjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamous Cell Carcinoma | 2027-11 |
Add all 5 to your calendar (.ics) → With an account.
Among the 46 studies testing nivolumab in Squamous Cell Carcinoma of Head and Neck, from their registry updates:
Among Bristol-Myers Squibb’s 12 in Squamous Cell Carcinoma of Head and Neck:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study has two, independent, cohorts, both in locally advanced squamous cell head and neck cancer. The purpose of the first cohort is to determine whether nivolumab in combination with radiotherapy is more effective than cetuximab in combination with radiotherapy, in subjects who are ineligible for cisplatin. The purpose of the second cohort is to determine whether nivolumab, cisplatin, and radiotherapy is more effective than cisplatin and radiotherapy in subjects who are eligible to receive cisplatin
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria could apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cohort 1
Biological: Nivolumab · Radiation: Radiotherapy
Cohort 1
Drug: Cetuximab · Radiation: Radiotherapy
Cohort 2
Biological: Nivolumab · Drug: Cisplatin · Radiation: Radiotherapy
Cohort 2
Drug: Cisplatin · Radiation: Radiotherapy
Number of Participants With an Adverse Event (AE)
Number of Participants with an Adverse Event
Time frame: 30 Days
Number of Participants With an Serious Adverse Event (SAE)
Number of Participants with an Serious Adverse Event (SAE)
Time frame: 30 days
Number of Participants With an Adverse Event Leading to Discontinuation
Number of Participants with an Adverse Event Leading to Discontinuation
Time frame: 30 Days
Number of Participants With an Adverse Event Leading to Dose Modification
Number of Participants with an Adverse Event Leading to dose modification
Time frame: 30 Days
Number of Participants With Select Adverse Events
Number of Participants with select adverse events. Select Adverse events include: gastrointestinal, hepatic, hypersensitivity/infusion reaction, pulmonary, renal, or skin.
Time frame: 30 Days
Number of Participants With an Immune-mediated Adverse Event (IMAE)
Number of Participants with an immune-mediated adverse event (IMAE)
Time frame: 100 days
Time to Onset and Time to Resolution of Immune-related Adverse Events
Time to onset and time to resolution of immune-related adverse events
Time frame: 100 days
Number of Participants Who Experienced Death
Number of Participants who experienced death
Time frame: 100 days
Number of Participants With an Abnormality in Specific Thyroid Tests
Number of participants with an abnormality in specific thyroid tests
Time frame: 30 Days
Number of Participants With an Abnormality in Specific Liver Tests
Number of participants with an abnormality in specific liver tests
Time frame: 30 days
| Milestone | Arm A (Cohort 1) | Arm B (Cohort 1) | Arm C (Cohort 2) | Arm D (Cohort 2) |
|---|---|---|---|---|
| Started | 12 | 10 | 27 | 25 |
| Completed | 12 | 10 | 27 | 24 |
| Not completed | 0 | 0 | 0 | 1 |
| Milestone | Arm A (Cohort 1) | Arm B (Cohort 1) | Arm C (Cohort 2) | Arm D (Cohort 2) |
|---|---|---|---|---|
| Started | 12 | 10 | 27 | 24 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 12 | 10 | 27 | 24 |
| Withdrew: Death | 0 | 0 | 1 | 0 |
| Withdrew: Disease progression | 0 | 2 | 0 | 1 |
| Withdrew: Study drug toxicity | 1 | 0 | 1 | 1 |
| Withdrew: Adverse event unrelated to study drug | 2 | 1 | 1 | 1 |
| Withdrew: Admin reason by sponsor | 0 | 7 | 0 | 19 |
| Withdrew: Other reason | 2 | 0 | 2 | 1 |
| Withdrew: Completed | 6 | 0 | 18 | 1 |
| Withdrew: Participant request to discontinue | 0 | 0 | 4 | 0 |
| Withdrew: Participant withdrew consent | 1 | 0 | 0 | 0 |
Number of Participants with an Adverse Event
| Participants | Arm A (Cohort 1) | Arm B (Cohort 1) | Arm C (Cohort 2) | Arm D (Cohort 2) |
|---|---|---|---|---|
| Number of Participants With an Adverse Event (AE) | 12 | 10 | 27 | 24 |
Number of Participants with an Serious Adverse Event (SAE)
| Participants | Arm A (Cohort 1) | Arm B (Cohort 1) | Arm C (Cohort 2) | Arm D (Cohort 2) |
|---|---|---|---|---|
| Number of Participants With an Serious Adverse Event (SAE) | 5 | 5 | 9 | 6 |
Number of Participants with an Adverse Event Leading to Discontinuation
| Participants | Arm A (Cohort 1) | Arm B (Cohort 1) | Arm C (Cohort 2) | Arm D (Cohort 2) |
|---|---|---|---|---|
| Number of Participants With an Adverse Event Leading to Discontinuation | 2 | 3 | 8 | 4 |
Number of Participants with an Adverse Event Leading to dose modification
| Participants | Arm A (Cohort 1) | Arm B (Cohort 1) | Arm C (Cohort 2) | Arm D (Cohort 2) |
|---|---|---|---|---|
| Number of Participants With an Adverse Event Leading to Dose Modification | 0 | 0 | 0 | 0 |
Number of Participants with select adverse events. Select Adverse events include: gastrointestinal, hepatic, hypersensitivity/infusion reaction, pulmonary, renal, or skin.
| Participants | Arm A (Cohort 1) | Arm B (Cohort 1) | Arm C (Cohort 2) | Arm D (Cohort 2) |
|---|---|---|---|---|
| Gastrointestinal | 4 | 3 | 3 | 1 |
| Hepatic | 1 | 2 | 2 | 3 |
| Hypersensitivity/Infusion Reaction | 1 | 3 | 0 | 0 |
| Pulmonary | 0 | 0 | 0 | 0 |
| Renal | 2 | 1 | 13 | 6 |
| Skin | 7 | 7 | 12 | 11 |
Number of Participants with an immune-mediated adverse event (IMAE)
| Participants | Arm A (Cohort 1) | Arm B (Cohort 1) | Arm C (Cohort 2) | Arm D (Cohort 2) |
|---|---|---|---|---|
| Non-Endocrine related IMAE | 1 | 0 | 3 | 0 |
| Endocrine related IMAE | 0 | 0 | 4 | 0 |
Time to onset and time to resolution of immune-related adverse events
No measurements were reported for this outcome.
Number of Participants who experienced death
| Participants | Arm A (Cohort 1) | Arm B (Cohort 1) | Arm C (Cohort 2) | Arm D (Cohort 2) |
|---|---|---|---|---|
| Number of Participants Who Experienced Death | 2 | 2 | 2 | 1 |
Number of participants with an abnormality in specific thyroid tests
| Participants | Arm A (Cohort 1) | Arm B (Cohort 1) | Arm C (Cohort 2) | Arm D (Cohort 2) |
|---|---|---|---|---|
| TSH > ULN | 5 | 1 | 7 | 1 |
| TSH > ULN WITH TSH <= ULN AT BASELINE | 5 | 1 | 7 | 1 |
| TSH >ULN WITH ATLEAST ONE FT3/FT4 TEST VALUE <LLN | 4 | 0 | 4 | 0 |
| TSH >ULN WITH ALL OTHER FT3/FT4 TEST VALUES >= LLN | 0 | 0 | 2 | 1 |
| TSH > ULN WITH FT3/FT4 TEST MISSING | 1 | 1 | 1 | 0 |
| TSH < LLN | 4 | 3 | 16 | 13 |
| TSH <LLN WITH TSH >= LLN AT BASELINE | 3 | 3 | 13 | 13 |
| TSH <LLN WITH ATLEAST ONE FT3/FT4 TEST VALUE > ULN | 0 | 0 | 9 | 2 |
| TSH <LLN WITH ALL OTHER FT3/FT4 TEST VALUES <= ULN | 4 | 1 | 6 | 7 |
| TSH < LLN WITH FT3/FT4 TEST MISSING | 0 | 2 | 1 | 4 |
Number of participants with an abnormality in specific liver tests
| Participants | Arm A (Cohort 1) | Arm B (Cohort 1) | Arm C (Cohort 2) | Arm D (Cohort 2) |
|---|---|---|---|---|
| ALT OR AST > 3XULN | 2 | 0 | 0 | 0 |
| ALT OR AST> 5XULN | 1 | 0 | 0 | 0 |
| ALT OR AST> 10XULN | 0 | 0 | 0 | 0 |
| ALT OR AST > 20XULN | 0 | 0 | 0 | 0 |
| TOTAL BILIRUBIN > 2XULN | 0 | 0 | 0 | 0 |
| ALT/AST ELEV>3XULN;TOTAL BILIRUBIN>2XULN IN 1 DAY | 0 | 0 | 0 | 0 |
| ALT/AST ELEV>3XULN;TOTAL BILIRUBIN>2XULN IN 30DAYS | 0 | 0 | 0 | 0 |
Collected over 101 days approximately. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A (Cohort 1) | 2/12 (16.7%) | 6/12 (50%) | 12/12 (100%) |
| Arm B (Cohort 1) | 2/10 (20%) | 5/10 (50%) | 10/10 (100%) |
| Arm C (Cohort 2) | 2/27 (7.4%) | 10/27 (37%) | 26/27 (96.3%) |
| Arm D (Cohort 2) | 1/24 (4.2%) | 7/24 (29.2%) | 24/24 (100%) |
| Event | Arm A (Cohort 1) | Arm B (Cohort 1) | Arm C (Cohort 2) | Arm D (Cohort 2) |
|---|---|---|---|---|
| Cardiac failureCardiac disorders | 0/12 | 1/10 | 0/27 | 0/24 |
| PneumoniaInfections and infestations | 0/12 | 1/10 | 0/27 | 0/24 |
| HyperglycaemiaMetabolism and nutrition disorders | 0/12 | 1/10 | 0/27 | 0/24 |
| Cerebrovascular accidentNervous system disorders | 0/12 | 1/10 | 0/27 | 0/24 |
| Pharyngeal necrosisRespiratory, thoracic and mediastinal disorders | 0/12 | 1/10 | 0/27 | 0/24 |
| Myocardial infarctionCardiac disorders | 1/12 | 0/10 | 0/27 | 0/24 |
| SepsisInfections and infestations | 1/12 | 0/10 | 0/27 | 0/24 |
| Transaminases increasedInvestigations | 1/12 | 0/10 | 0/27 | 0/24 |
| Decreased appetiteMetabolism and nutrition disorders | 0/12 | 0/10 | 0/27 | 2/24 |
| Oropharyngeal squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/12 | 0/10 | 0/27 | 0/24 |
| Event | Arm A (Cohort 1) | Arm B (Cohort 1) | Arm C (Cohort 2) | Arm D (Cohort 2) |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 3/12 | 1/10 | 17/27 | 11/24 |
| ConstipationGastrointestinal disorders | 4/12 | 2/10 | 13/27 | 12/24 |
| DysphagiaGastrointestinal disorders | 6/12 | 3/10 | 11/27 | 5/24 |
| FatigueGeneral disorders | 4/12 | 5/10 | 8/27 | 3/24 |
| Radiation skin injuryInjury, poisoning and procedural complications | 4/12 | 5/10 | 8/27 | 12/24 |
| AnaemiaBlood and lymphatic system disorders | 4/12 | 3/10 | 12/27 | 8/24 |
| Dry mouthGastrointestinal disorders | 4/12 | 3/10 | 12/27 | 9/24 |
| DysgeusiaNervous system disorders | 2/12 | 2/10 | 12/27 | 6/24 |
| Decreased appetiteMetabolism and nutrition disorders | 4/12 | 2/10 | 9/27 | 10/24 |
| Weight decreasedInvestigations | 3/12 | 2/10 | 11/27 | 7/24 |
| Age, Continuous(Years) | Arm A (Cohort 1) | Arm B (Cohort 1) | Arm C (Cohort 2) | Arm D (Cohort 2) | Total |
|---|---|---|---|---|---|
| Mean | 74.5 ± 8.3 | 74.7 ± 6.5 | 59.0 ± 6.6 | 60.8 ± 7.0 | 64.2 ± 9.7 |
| Sex: Female, Male(Participants) | Arm A (Cohort 1) | Arm B (Cohort 1) | Arm C (Cohort 2) | Arm D (Cohort 2) | Total |
|---|---|---|---|---|---|
| Female | 2 | 2 | 3 | 2 | 9 |
| Male | 10 | 8 | 24 | 23 | 65 |
| Ethnicity (NIH/OMB)(Participants) | Arm A (Cohort 1) | Arm B (Cohort 1) | Arm C (Cohort 2) | Arm D (Cohort 2) | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 5 | 4 | 9 | 2 | 20 |
| Unknown or Not Reported | 7 | 6 | 18 | 23 | 54 |
| Race (NIH/OMB)(Participants) | Arm A (Cohort 1) | Arm B (Cohort 1) | Arm C (Cohort 2) | Arm D (Cohort 2) | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 3 | 4 | 6 | 15 | 28 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 2 | 0 | 2 |
| White | 8 | 5 | 16 | 7 | 36 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 1 | 3 | 3 | 8 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2017 to primary completion in Oct 2019, 21 months.
Results were first posted in Aug 2021, 1 year 9 months after primary completion.
Of 78 phase 3 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 117. This study's 21 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Nivolumab · Cetuximab · Cisplatin
Squamous Cell Carcinoma of Head and Neck →